BLAINJECTIONINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NEMLUVIO (nemolizumab-ilto) by Galderma is interleukin-31 receptor alpha antagonists [moa]. First approved in 2024.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEMLUVIO (nemolizumab-ilto) is a monoclonal antibody that antagonizes the interleukin-31 receptor alpha (IL-31RA), a key driver of chronic pruritus. The drug targets the IL-31 signaling pathway to reduce itching in patients with moderate-to-severe atopic dermatitis and other pruritic conditions. It represents a novel mechanism for addressing itch that has not been adequately controlled by existing therapies.
Growth
As a newly approved biologic in the growth phase, the brand team is building infrastructure and market access; early-stage hiring in field sales, health economics, and market development roles.
Mechanism of Action
Interleukin-31 Receptor alpha Antagonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NEMLUVIO during its growth phase offers career visibility and the opportunity to shape a novel mechanism launch in a high-stakes dermatology market. Team members will gain experience in biologic commercialization, payer negotiation, and rare mechanism education across a newly built franchise.
Brand ManagerField Sales Representative
Worked on NEMLUVIO at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.